Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is stepping into December 15, 2025 with a very “micro-cap biotech” mix of catalysts and pressure points: a Nasdaq deadline calendar, an FDA regulatory milestone for its lead sublingual aspirin program, and capital-structure dynamics